190 related articles for article (PubMed ID: 35281000)
1. Identification of Distinct Immune Cell Subsets Associated With Asymptomatic Infection, Disease Severity, and Viral Persistence in COVID-19 Patients.
Wang X; Bai H; Ma J; Qin H; Zeng Q; Hu F; Jiang T; Mao W; Zhao Y; Chen X; Qi X; Li M; Xu J; Hao J; Wang Y; Ding X; Liu Y; Huang T; Fang C; Ge C; Li D; Hu K; Ren X; Zhang B; Zhang B; Shi B; Zhang C
Front Immunol; 2022; 13():812514. PubMed ID: 35281000
[TBL] [Abstract][Full Text] [Related]
2. Suppressive Monocytes Impair MAIT Cells Response via IL-10 in Patients with Severe COVID-19.
Yang Q; Wen Y; Qi F; Gao X; Chen W; Xu G; Wei C; Wang H; Tang X; Lin J; Zhao J; Zhang M; Zhang S; Zhang Z
J Immunol; 2021 Oct; 207(7):1848-1856. PubMed ID: 34452933
[TBL] [Abstract][Full Text] [Related]
3. T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19.
Zenarruzabeitia O; Astarloa-Pando G; Terrén I; Orrantia A; Pérez-Garay R; Seijas-Betolaza I; Nieto-Arana J; Imaz-Ayo N; Pérez-Fernández S; Arana-Arri E; Borrego F
Front Immunol; 2021; 12():655934. PubMed ID: 33777054
[TBL] [Abstract][Full Text] [Related]
4. Immune Response in Severe and Non-Severe Coronavirus Disease 2019 (COVID-19) Infection: A Mechanistic Landscape.
Mukund K; Nayak P; Ashokkumar C; Rao S; Almeda J; Betancourt-Garcia MM; Sindhi R; Subramaniam S
Front Immunol; 2021; 12():738073. PubMed ID: 34721400
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells and unconventional T cells in COVID-19.
Björkström NK; Ponzetta A
Curr Opin Virol; 2021 Aug; 49():176-182. PubMed ID: 34217135
[TBL] [Abstract][Full Text] [Related]
6. Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity.
Flament H; Rouland M; Beaudoin L; Toubal A; Bertrand L; Lebourgeois S; Rousseau C; Soulard P; Gouda Z; Cagninacci L; Monteiro AC; Hurtado-Nedelec M; Luce S; Bailly K; Andrieu M; Saintpierre B; Letourneur F; Jouan Y; Si-Tahar M; Baranek T; Paget C; Boitard C; Vallet-Pichard A; Gautier JF; Ajzenberg N; Terrier B; Pène F; Ghosn J; Lescure X; Yazdanpanah Y; Visseaux B; Descamps D; Timsit JF; Monteiro RC; Lehuen A
Nat Immunol; 2021 Mar; 22(3):322-335. PubMed ID: 33531712
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte Subset Alteration and Monocyte CD4 Expression Reduction in Patients with Severe COVID-19.
Kazancioglu S; Yilmaz FM; Bastug A; Sakallı A; Ozbay BO; Buyuktarakci C; Bodur H; Yilmaz G
Viral Immunol; 2021 Jun; 34(5):342-351. PubMed ID: 33264073
[TBL] [Abstract][Full Text] [Related]
8. Single-Cell Transcriptomic Profiling of MAIT Cells in Patients With COVID-19.
Shi J; Zhou J; Zhang X; Hu W; Zhao JF; Wang S; Wang FS; Zhang JY
Front Immunol; 2021; 12():700152. PubMed ID: 34394094
[TBL] [Abstract][Full Text] [Related]
9. Distinct immune signatures discriminate between asymptomatic and presymptomatic SARS-CoV-2
Yu S; Di C; Chen S; Guo M; Yan J; Zhu Z; Liu L; Feng R; Xie Y; Zhang R; Chen J; Wang M; Wei D; Fang H; Yin T; Huang J; Chen S; Lu H; Zhu J; Qu J
Cell Res; 2021 Nov; 31(11):1148-1162. PubMed ID: 34561618
[TBL] [Abstract][Full Text] [Related]
10. Severe COVID-19 Recovery Is Associated with Timely Acquisition of a Myeloid Cell Immune-Regulatory Phenotype.
Trombetta AC; Farias GB; Gomes AMC; Godinho-Santos A; Rosmaninho P; Conceição CM; Laia J; Santos DF; Almeida ARM; Mota C; Gomes A; Serrano M; Veldhoen M; Sousa AE; Fernandes SM
Front Immunol; 2021; 12():691725. PubMed ID: 34248984
[TBL] [Abstract][Full Text] [Related]
11. Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.
Yin SW; Zhou Z; Wang JL; Deng YF; Jing H; Qiu Y
Virol J; 2021 Jun; 18(1):126. PubMed ID: 34118952
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Immune Profiling Reveals CD56
Dutt TS; LaVergne SM; Webb TL; Baxter BA; Stromberg S; McFann K; Berry K; Tipton M; Alnachoukati O; Zier L; Ebel G; Dunn J; Henao-Tamayo M; Ryan EP
J Immunol; 2022 Feb; 208(3):685-696. PubMed ID: 34987111
[TBL] [Abstract][Full Text] [Related]
13. Increased Expression of Tim-3 Is Associated With Depletion of NKT Cells In SARS-CoV-2 Infection.
Yang J; Chang T; Tang L; Deng H; Chen D; Luo J; Wu H; Tang T; Zhang C; Li Z; Dong L; Yang XP; Tang ZH
Front Immunol; 2022; 13():796682. PubMed ID: 35250975
[TBL] [Abstract][Full Text] [Related]
14. Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection.
Littera R; Chessa L; Deidda S; Angioni G; Campagna M; Lai S; Melis M; Cipri S; Firinu D; Santus S; Lai A; Porcella R; Rassu S; Meloni F; Schirru D; Cordeddu W; Kowalik MA; Ragatzu P; Vacca M; Cannas F; Alba F; Carta MG; Del Giacco S; Restivo A; Deidda S; Palimodde A; Congera P; Perra R; Orrù G; Pes F; Loi M; Murru C; Urru E; Onali S; Coghe F; Giglio S; Perra A
PLoS One; 2021; 16(8):e0255608. PubMed ID: 34352002
[TBL] [Abstract][Full Text] [Related]
15. Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection.
Patterson BK; Francisco EB; Yogendra R; Long E; Pise A; Rodrigues H; Hall E; Herrera M; Parikh P; Guevara-Coto J; Triche TJ; Scott P; Hekmati S; Maglinte D; Chang X; Mora-Rodríguez RA; Mora J
Front Immunol; 2021; 12():746021. PubMed ID: 35082777
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal dynamic single-cell mass cytometry analysis of peripheral blood mononuclear cells in COVID-19 patients within 6 months after viral RNA clearance.
Zhou D; Zhao S; He K; Liu Q; Zhang F; Pu Z; Xiao L; Zhang L; Chen S; Qian X; Wu X; Shen Y; Yu L; Zhang H; Jin J; Xu M; Wang X; Zhu D; Xie Z; Xu X
BMC Infect Dis; 2024 Jun; 24(1):567. PubMed ID: 38844850
[TBL] [Abstract][Full Text] [Related]
17. Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73
Ahmadi P; Hartjen P; Kohsar M; Kummer S; Schmiedel S; Bockmann JH; Fathi A; Huber S; Haag F; Schulze Zur Wiesch J
Cells; 2020 Jul; 9(8):. PubMed ID: 32707842
[TBL] [Abstract][Full Text] [Related]
18. Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia.
Kreutmair S; Unger S; Núñez NG; Ingelfinger F; Alberti C; De Feo D; Krishnarajah S; Kauffmann M; Friebel E; Babaei S; Gaborit B; Lutz M; Jurado NP; Malek NP; Goepel S; Rosenberger P; Häberle HA; Ayoub I; Al-Hajj S; Nilsson J; Claassen M; Liblau R; Martin-Blondel G; Bitzer M; Roquilly A; Becher B
Immunity; 2021 Jul; 54(7):1578-1593.e5. PubMed ID: 34051147
[TBL] [Abstract][Full Text] [Related]
19. Distinct Expression Patterns of Interleukin-22 Receptor 1 on Blood Hematopoietic Cells in SARS-CoV-2 Infection.
Albayrak N; Orte Cano C; Karimi S; Dogahe D; Van Praet A; Godefroid A; Del Marmol V; Grimaldi D; Bondue B; Van Vooren JP; Mascart F; Corbière V
Front Immunol; 2022; 13():769839. PubMed ID: 35422799
[TBL] [Abstract][Full Text] [Related]
20. Integrated analysis of circulating immune cellular and soluble mediators reveals specific COVID19 signatures at hospital admission with utility for prediction of clinical outcomes.
Uranga-Murillo I; Morte E; Hidalgo S; Pesini C; García-Mulero S; Sierra JL; Santiago L; Arias M; De Miguel D; Encabo-Berzosa MDM; Gracia-Tello B; Sanz-Pamplona R; Martinez-Lostao L; Galvez EM; Paño-Pardo JR; Ramirez-Labrada A; Pardo J
Theranostics; 2022; 12(1):290-306. PubMed ID: 34987646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
